Online citations, reference lists, and bibliographies.
← Back to Search

The Impact Of Clinical Factors, Riluzole And Therapeutic Interventions On ALS Survival: A Population Based Study In Modena, Italy

E. Georgoulopoulou, N. Fini, M. Vinceti, M. Monelli, Paolo Vacondio, G. Bianconi, P. Sola, P. Nichelli, J. Mandrioli
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Abstract The prognostic role of riluzole, enteral nutrition (EN), non-invasive ventilation (NIV) and interdisciplinary care in ALS is still debated. A population based study has been performed focusing on ALS survival, with particular attention to prognostic factors and therapeutic intervention. All patients diagnosed with ALS between 2000 and 2009 and residing in Modena, Italy, have been registered. A centre for motor neuron disease (MND) has been active in our province since 2000, in addition to a prospective registry collecting all incident cases. One hundred and ninety-three incident cases have been collected during the 10 years of the study. Results demonstrated that median survival was 41 months (the overall three-year and five-year survival rates being 54.36% and 28.81%, respectively). Based on univariate analysis, factors related to survival were: age at diagnosis, gender, site of onset, phenotype, riluzole treatment and tracheostomy. In the Cox multivariable model, the factors independently related to a longer survival were age (p < 0.01), site of onset (p = 0.02) and riluzole treatment (p < 0.01), with a median gain in survival of 29 months (patients aged < 55 years compared with patients ≥ 55 years), 20 months (spinal versus bulbar onset), and 12 months (riluzole, yes vs. no), respectively. In conclusion, the study has confirmed the prognostic role of clinical features, but has surprisingly demonstrated that riluzole prolonged life significantly longer than NIV and EN. This observational study described the effects of ALS management in a setting that may approximate routine clinical practice more closely than randomized controlled trial (RCT); effects of uncontrolled potential confounders, however, cannot be excluded.
This paper references
10.1056/NEJM199403033300911
Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell?
L. Rowland (1994)
10.1056/NEJM199403033300901
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
G. Bensimon (1994)
Hardiman O . Riluzole and prognosis in ALS: fi ndings of the Irish ALS register over a fi ve-year study period
B J Traynor (1995)
10.1016/S0140-6736(96)91680-3
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral SclerosisRiluzole Study Group (1996)
Amyotrophic Lateral Sclerosis/Riluzole Study Group II . Dose-ranging study of riluzole in amyotrophic lateral sclerosis
(1996)
Database 1999 – 2000: an analysis of the effect on survival of interventions in amyotrophic lat- eral sclerosis
Al-Chalabi A . The Kings (2001)
Riluzole and prognosis in ALS: fi ndings of the Irish ALS register over a fi ve-year study period (1995
O Hardiman (2001)
Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) Ϫ motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study
(2001)
Al-Chalabi A . The Kings ' Database 1999 -2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis
M R Turner (2001)
10.1007/s004150200071
A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis
G. Bensimon (2002)
Riluzole/ALS Study Group II . A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis
P Truffi net (2002)
10.1136/jnnp.74.9.1258
Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000
B. Traynor (2003)
10.1136/jnnp.2005.083402
Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities
A. Chiò (2006)
10.1016/S1474-4422(05)70326-4
Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial
S. Bourke (2006)
10.1080/14660820500396984
Audit of outcomes in motor neuron disease (MND) patients treated with riluzole
D. Mitchell (2006)
10.1007/s00415-006-0401-y
ALS multidisciplinary clinic and survival
S. Zoccolella (2006)
10.1002/14651858.CD004030.PUB2
Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.
S. Langmore (2006)
ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy.
S. Zoccolella (2007)
10.1111/j.1468-1331.2006.01575.x
Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy
S. Zoccolella (2007)
10.1136/jnnp.2006.104828
Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
G. Logroscino (2008)
Age at onset infl uences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis
G Bensimon (2008)
10.1002/14651858.CD007425.pub2
Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease.
L. Ng (2009)
10.3109/17482960802566824
Prognostic factors in ALS: A critical review
A. Chiò (2009)
10.1016/j.jns.2008.09.024
Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis
N. Atsuta (2009)
Mechanical 3. ventilation for amyotrophic lateral sclerosis/motor neuron disease
A Radunovic (2009)
10.1136/jnnp.2009.175984
Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy
A. Chiò (2010)
10.1136/jnnp.2010.235952
Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study
A. Chiò (2011)
10.3109/17482968.2010.502940
The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
E. Beghi (2011)
10.3109/17482968.2011.593037
Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study
Eleni Georgoulopoulou (2011)
10.1212/WNL.0b013e318232ab9b
ALS clinical trials
A. Chiò (2011)
trophic lateral sclerosis/motor neuron disease
SC Bourke (2011)
10.1111/j.1468-1331.2011.03501.x
EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force
P. Andersen (2012)



This paper is referenced by
10.3390/jcm10081623
Clinical Determinants of Disease Progression in Amyotrophic Lateral Sclerosis—A Retrospective Cohort Study
Maria Viktoria Requardt (2021)
10.3389/fneur.2021.633854
Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis
M. Povedano Panadés (2021)
10.1503/cmaj.191721
Canadian best practice recommendations for the management of amyotrophic lateral sclerosis
C. Shoesmith (2020)
10.1177/2192568219835516
The Impact of Riluzole on Neurobehavioral Outcomes in Preclinical Models of Traumatic and Nontraumatic Spinal Cord Injury: Results From a Systematic Review of the Literature
Lindsay Tetreault (2020)
10.1080/21678421.2020.1771734
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis
J. Andrews (2020)
10.1111/ene.14647
Non‐invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany
S. Spittel (2020)
10.1093/toxsci/kfaa019
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
Diane M. Longo (2020)
10.5772/intechopen.91921
Introduction to Novel Motor Neuron Disease
Humberto Foyaca Sibat (2020)
10.3390/j3030021
Riluzole Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis: Texture and Compatibility with Food Thickeners Evaluation
G. Colombo (2020)
10.1503/cmaj.191721-f
Recommandations canadiennes pour les pratiques optimales de prise en charge de la sclérose latérale amyotrophique
Christen Shoesmith (2020)
A supervised learning approach for prognostic prediction in ALS using disease progression groups and patient profiles
S. Pires (2018)
10.3389/fneur.2018.00578
Associative Increases in Amyotrophic Lateral Sclerosis Survival Duration With Non-invasive Ventilation Initiation and Usage Protocols
Nishad Khamankar (2018)
10.1007/s00415-018-8778-y
Riluzole and other prognostic factors in ALS: a population-based registry study in Italy
J. Mandrioli (2018)
What's in a face? : psychophysiological applications of neuroscience for diagnostics and therapies
Javier A. Elkin (2018)
10.2147/DNND.S135748
Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
M. Hinchcliffe (2017)
Beyond SOD1: Detailed Characterisation of a TDP-43 Transgenic Mouse Model of Motor Neurone Disease
J. Stephenson (2017)
10.1177/2472555216685044
Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery
T. Kunkanjanawan (2017)
10.1242/jcs.190298
New links between SOD1 and metabolic dysfunction from a yeast model of amyotrophic lateral sclerosis
Emma L. Bastow (2016)
10.1007/S40267-016-0312-7
Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use
G. Keating (2016)
10.1016/j.jocn.2015.07.007
Motor neurone disease in Lancashire and South Cumbria in North West England and an 8year experience with enteral nutrition
S. Chhetri (2016)
10.1016/j.ejmech.2016.06.017
Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.
Vijay Kumar (2016)
Assessing Drug Responses in WT-NPCs and HD-NPCs Using an MTT Assay and G 6 PD Cytotoxicity Assay
T. Kunkanjanawan (2016)
10.1016/S1474-4422(14)70221-2
End-of-life management in patients with amyotrophic lateral sclerosis
S. Connolly (2015)
Epidémiologie de la sclérose latérale amyotrophique : Facteurs de risque, incidence et phénotypes
B. Hamidou (2015)
10.1371/journal.pone.0141500
Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study
M. Moura (2015)
Amyotrophic Lateral Sclerosis : the Current World Situation coMMentary
Antonio Gilvan Teixeira (2015)
10.1212/WNL.0000000000001522
Head injury does not alter disease progression or neuropathologic outcomes in ALS
C. Fournier (2015)
10.1111/ane.12381
bFGF in the CSF and serum of sALS patients
Z. Gong (2015)
10.1111/resp.13206_97
NON‐INVASIVE VENTILATION IN MOTOR NEURONE DISEASE/AMYOTROPHIC LATERAL SCLEROSIS: AN AUSTRALASIAN PERSPECTIVE
W. Chow (2015)
10.1002/ana.24273
Quantifying Disease Progression in Amyotrophic Lateral Sclerosis
N. Simon (2014)
Étude LENSLA : caractérisation des patients atteints de sclérose latérale amyotrophique évoluant depuis plus de 5 ans suivis au centre de référence de Bordeaux
C. Coignion (2014)
10.1007/s13311-014-0332-8
Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease
J. Rosenfeld (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar